Orchestra BioMed (OBIO) Q4 2025 earnings summary

Executive summary

• Ended 2025 with $106.5 million in cash, further bolstered by $35 million expected from Medtronic and Ligand in Q2 2026, plus up to $10.7 million from Haemonetics' Vivasure acquisition in 2026.

• Achieved $33.5 million in non-recurring revenue in 2025, mainly from the new Virtue SAB agreement with Terumo.

• Strengthened financial position through nearly $150 million in new capital and commitments from strategic transactions with Medtronic, Ligand, and Terumo.

• Focused on pivotal trial execution for AVIM Therapy and Virtue SAB, with accelerated enrollment in the BACKBEAT study and initiation of the Virtue Trial.

Financial highlights

• 2025 revenue was $33.5 million, up 1,539% from $2.6 million in 2024, driven by deferred revenue recognition and new agreements.

• Research and development expenses rose 36% to $58.2 million, reflecting increased clinical trial activity.

• Selling, general, and administrative expenses increased 12% to $26.9 million, mainly due to higher professional fees.

• Net loss attributable to common stockholders was $52.7 million ($1.11 per share), a 14% improvement from $61.0 million ($1.66 per share) in 2024.

• Net cash used in operating activities and fixed asset purchases (excluding certain payments) was $66.9 million, up from $50.8 million in 2024.

Outlook and guidance

• Additional $35 million in proceeds expected from Medtronic and Ligand by May 1, 2026, subject to agreement conditions.

• Up to $10.7 million in proceeds anticipated in 2026 from Haemonetics' acquisition of Vivasure, with $4.7 million already received.

• Updates on pivotal trial enrollment and results for BACKBEAT and Virtue SAB expected in future quarterly reports.